Company:  EQUILLIUM, INC. (EQ)
Form Type:  SC 13G/A
Filing Date:  2/14/2020 
CIK:  0001746466 
Address:  2223 AVENIDA DE LA PLAYA
SUITE 105
 
City, State, Zip:  LA JOLLA, California 92037 
Telephone:  (858) 412-5302 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$5.42  
Change: 
0.17 (3.24%)  
Trade Time: 
May 14  
Market Cap: 
$157.40M
Trade EQ now with 

© 2021  
Description of Business
We are a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. Our initial product candidate, itolizumab (EQ001), is a clinical-stage, first-in-class monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. CD6 plays a central role in the modulation of effector T cell, or Teff cell, activity and trafficking. Activated Teff cells drive a number of immuno-inflammatory diseases across therapeutic areas including transplant science, systemic autoimmunity, pulmonary, neurologic, gastrointestinal, renal, vascular, ophthalmic and dermatologic disorders. Therefore, we believe itolizumab (EQ001) may have broad therapeutic utility in treating a large and diverse set of severe immuno-inflammatory diseases.
Register and access this filing in:     
  FORM SC 13G/A